Chart 1 of Today’s Presentation: I noticed that this chart indicates that among Alzheimer’s phase 2a patients administered AVXL 2-73, the direction of ADAS-Cog improvement accelerated slightly between 57 weeks and 70 weeks. Apparently, Anavex is following and including patients involved in extensions? See the chart that shows Anavex 272-002 commencing at 57 weeks and Anavex 272-003 (Extension) commencing at 70 weeks??
Market Data 
Markets 
AI
